Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9th at 11:20 am EST (8:20 am PST). A live webcast of...

Capsugel and Pulmatrix, Inc. ("Pulmatrix") (NASDAQ: PULM) have formed a collaboration to develop novel inhaled therapeutics to treat serious pulmonary diseases. The agreement provides Capsugel...

Pulmatrix, Inc. (NASDAQ: PULM) reports that enrollment is underway in the Company's European pilot bioequivalence study of PUR0200, a proprietary iSPERSE™ (Inhaled Small Particles Easily...

Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at Biotech Showcase 2016 on Monday, January 11th at 2:30 pm PST (5:30 pm EST). A live webcast of the presentation may be accessed in...

What: Pulmatrix, Inc. (Nasdaq: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

Pulmatrix, Inc. (Nasdaq: PULM) announced that the Company's common stock has qualified for and will begin trading today on the Nasdaq Global Market. The trading symbol remains PULM. Prior to...

Pulmatrix, Inc. (NASDAQ: PULM), a biopharmaceutical company developing inhaled therapies for pulmonary disease, today announced the appointment of Mark Iwicki as chairman of its board of...

Pulmatrix, Inc. (NASDAQ: PULM) reports third quarter financial results and provides an update on the progress year to date on the business and its drug development pipeline. Since the beginning of...

Pulmatrix, Inc., (NASDAQ: PULM) will be webcasting the Company's investor presentation at two upcoming investor conferences. Pulmatrix will be presenting at the Dawson James 2015 Small Cap Growth...

Pulmatrix, Inc. (NASDAQ: PULM) today announced preclinical data showing that PUR1900 (iSPERSE™-formulated itraconazole), which is being developed as the first inhaled antifungal medication for...

Celdara Medical, LLC and Pulmatrix, Inc. (NASDAQ: PULM) today announced that the National Heart Lung and Blood Institute of the National Institutes of Health has awarded a three-year, $1.7 million...

Pulmatrix, Inc. (NASDAQ: PULM) will report data from a Phase 1B study evaluating PUR0200, an iSPERSE formulation of a long acting muscarinic antagonist (LAMA) bronchodilator, on September 29th at...

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease, today announced that preclinical data...

Pulmatrix, Inc., (NASDAQ: PULM) will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 11:40 am EDT. As part of the presentation, Robert...

Pulmatrix, Inc. (NASDAQ: PULM) has been granted U.S. patent 9,119,778, for the Company's underlying iSPERSE™ inhaled dry powder technology. The patent broadly covers small, dense and dispersible...

Pulmatrix, Inc., (NASDAQ: PULM) reports second quarter financial results and provides an update on the progress year to date on the business and its drug development pipeline. "During the second...

Pulmatrix, Inc., (NASDAQ: PULM) will webcast an investor presentation August 6, 2015 at 10:45 am EDT. As part of the presentation, Robert Clarke, Chief Executive Officer, will review Pulmatrix's...

Pulmatrix, Inc. (NASDAQ: PULM) has been granted two patents from the U.S. Patent and Trademark Office (U.S. Patent # 8,992,983 and U.S. patent # 9,061,352), which cover the composition of matter...

Dear Fellow Shareholders, The Pulmatrix management team and I would like to thank our founding institutional shareholders for their continued support and investment. Additionally, we want to...

Pulmatrix, Inc. (NASDAQ: PULM) announced today the appointment of William Duke, Jr., as chief financial officer. Mr. Duke previously served as chief financial officer of Valeritas, Inc., a company...

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced the appointment of Michael...

Pulmatrix (Nasdaq: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S....

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an...

Pulmatrix, Inc., (NASDAQ: PULM), previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private...

Santa Rosa, Ca., March --- March 16, 2015 – Ruthigen, Inc. (NASDAQ: RTGN) (“Ruthigen”), and Pulmatrix, Inc., (“Pulmatrix”), a Lexington, Massachusetts based clinical stage...

Lexington, MA, May 5, 2014 – Pulmatrix today presented data at the 2014 Respiratory Drug Delivery Conference in Fajardo, Puerto Rico. The poster presentation includes development data on...

Lexington, MA, May 5, 2014 – Pulmatrix today announced the successful completion and positive results of the second part of a two-part Phase 1B clinical study in chronic obstructive...